# Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

> **NCT05098613** · PHASE1 · RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 68 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma
- B-cell Non-Hodgkin Lymphoma (B-NHL)
- Mantle Cell Lymphoma (MCL)
- CNS Lymphoma

## Interventions

- **DRUG:** CD19x22 CAR T Cells

## Key facts

- **NCT ID:** NCT05098613
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-21
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05098613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05098613, "Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05098613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*